LncRNA FOXD1-AS1 regulates pancreatic cancer stem cell properties and 5-FU resistance by regulating the miR-570-3p/SPP1 axis as a ceRNA

Liu Ouyang,Min-min Sun,Ping-sheng Zhou,Yi-wei Ren,Xin-yu Liu,Wan-ying Wei,Zhen-shun Song,Kai Lu,Li-xue Yang
DOI: https://doi.org/10.1186/s12935-023-03181-5
IF: 6.429
2024-01-04
Cancer Cell International
Abstract:Cancer stem cells (CSCs) play a pivotal role in the pathogenesis of human cancers. Previous studies have highlighted the role of long non-coding RNA (lncRNA) in modulating the stemness of CSCs. In our investigation, we identified an upregulation of lncRNA FOXD1-AS1 in CSCs. The enforced expression of lncRNA FOXD1-AS1 promotes tumorigenesis and self-renewal in pancreatic cancer CSCs. Conversely, the knockdown of lncRNA FOXD1-AS1 inhibits tumorigenesis and self-renewal in pancreatic cancer CSCs. Furthermore, our findings reveal that lncRNA FOXD1-AS1 enhances self-renewal and tumorigenesis in pancreatic cancer CSCs by up-regulating osteopontin/secreted phosphoprotein 1(SPP1) and acting as a ceRNA to sponge miR-570-3p in pancreatic cancer (PC) CSCs. Additionally, lncRNA FOXD1-AS1 depleted pancreatic cancer cells exhibit heightened sensitivity to 5-FU-indued cell growth inhibition and apoptosis. Analysis of patient-derived xenografts (PDX) indicates that a low level of lncRNA FOXD1-AS1 may serve as a predictor of 5-FU benefits in PC patients. Moreover, the introduction of SPP1 can reverse the sensitivity of lncRNA FOXD1-AS1-knockdown PC cells to 5-FU-induced cell apoptosis. Importantly, molecular studies have indicated that the elevated levels of lncRNAFOXD1-AS1 in PC are facilitated through METTL3 and YTHDF1-dependent m 6 A methylation. In summary, our results underscore the critical functions of lncRNA FOXD1-AS1 in the self-renewal and tumorigenesis of pancreatic cancer CSCs, positioning lncRNA FOXD1-AS1 as a promising therapeutic target for PC.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the role of long non - coding RNA (lncRNA) FOXD1 - AS1 in pancreatic cancer stem cells (CSCs) and its impact on 5 - fluorouracil (5 - FU) chemotherapy resistance. Specifically: 1. **Expression of lncRNA FOXD1 - AS1 in pancreatic cancer stem cells**: - The study found that lncRNA FOXD1 - AS1 is highly expressed in pancreatic cancer stem cells and is positively correlated with the expression of stem cell markers CD133 and CD90. 2. **Impact of lncRNA FOXD1 - AS1 on self - renewal and tumorigenesis of pancreatic cancer stem cells**: - The experimental results show that knocking down lncRNA FOXD1 - AS1 can inhibit the self - renewal ability and tumorigenic ability of pancreatic cancer stem cells; conversely, over - expressing lncRNA FOXD1 - AS1 enhances these abilities. 3. **lncRNA FOXD1 - AS1 acts as a competing endogenous RNA (ceRNA) by regulating the miR - 570 - 3p/SPP1 axis**: - Mechanistic studies indicate that lncRNA FOXD1 - AS1 up - regulates the expression of SPP1 by sponging miR - 570 - 3p, thereby promoting the self - renewal and tumorigenesis of pancreatic cancer stem cells. 4. **Impact of lncRNA FOXD1 - AS1 on 5 - FU chemotherapy sensitivity**: - The study found that the high expression of lncRNA FOXD1 - AS1 is related to 5 - FU resistance. Knocking down lncRNA FOXD1 - AS1 can increase the sensitivity of pancreatic cancer cells to 5 - FU, and introducing SPP1 can reverse this sensitivity. 5. **Regulatory mechanism of lncRNA FOXD1 - AS1**: - Further studies show that the high expression of lncRNA FOXD1 - AS1 in pancreatic cancer is regulated by METTL3 - and YTHDF1 - dependent m6A methylation. In summary, this paper aims to reveal the function of lncRNA FOXD1 - AS1 in pancreatic cancer stem cells and its impact on 5 - FU chemotherapy resistance, providing new potential targets for the treatment of pancreatic cancer.